Affective Disorder Conference of China for 2017 was held in Kunming, Yunan from August 3 to 5. More than 500 experts and doctors in mental health from all over the country came together to jointly explore the latest research developments in the clinical diagnosis and treatment of affective disorder.
“Hansoh Depressive Disorder Forum” was held on August 4. The experts had an in-depth discussion on the pathogenesis of depressive disorder and the selection of antidepressant drugs, taking new psychotropic drugs like Hansoh Pharma’s Ameining (Agomelatine Tablets) as examples. The experts had high praise for the action mechanism and clinical efficacy of Ameining after the discussion.
For many years, Hansoh Pharma has been actively engaged in the mental disease field, providing support to technical problem solving, academic exchanges and talent development. At the beginning of July, the Company held “Hansoh Forum for Precise Diagnosis of Mental Disease” during the 14th academic annual conference of CSNP. Mental disease prevention and control experts shared the latest academic developments in precise diagnosis. The forum has received strong positive feedback from the industry.
Hansoh Pharma has targeted the international leading edge in the mental disease field, having introduced and developed a series of market-leading brands. A key product, Oulanning (Olanzapine Tablets), was launched in 2001. With its outstanding quality and low cost, the product received wide recognition from domestic doctors and patients and became a market-leading brand in less than 2 years after its launch. It has helped millions of patents return to healthy lives and saved the society billions of dollars in treatment costs. Owing to its great contribution to society, the Oulanning R&D project was granted a National Science and Technology Progress Award in 2014.
Hansoh Pharma’s new psychotropic drug, Ameining, was launched in China in 2015. Compared with conventional drugs, Ameining can better rebuild the circadian rhythm functions. Through the unique mechanism of improvement plus reconstruction, it has better antidepressant efficacy than conventional drugs. Thanks to its safety, efficacy and affordable treatment cost, Ameining is good news for depression patients.
Hansoh Pharma also actively participates in public activities related to mental health. It made a huge investment to launch the “Great Love - Spirit” a special public welfare fund mental health in China, which aims to gather together an unstoppable flow of support and care from “everyone”—psychiatrists, media circles, the philanthropic community, business circles and governmental agencies and others—to advance the cause of mental health in China. In the future, Hansoh Pharma will continue to adhere to its corporate mission of “serving the society and promoting health”. It will continue to care for people’s mental health and strive to improve social stability and mental health levels.
